Jul 23, 2008 - CombinatoRx, Incorporated (NASDAQ: CRXX) provided a detailed review of selected therapeutic programs and a general company update at its annual Research and Development (R&D) day at its corporate headquarters in Cambridge, MA.Presentation highlights included:...
CRx-401
The company conducted a comprehensive review of the ongoing Phase 2a clinical trial of CRx-401 as "add-on" to metformin therapy in Type-2 diabetes. The presentation also included a discussion of the potentially favorable positioning of CRx-401 with respect to the new FDA guidelines related to cardiovascular outcomes. With dozens of years of clinical experience behind the components and positive cardiovascular outcomes data previously demonstrated with bezafibrate in particular, CRx-401 may offer a reduced risk development pathway. Clinical data from this trial are expected in the second half of 2008... CombinatoRx's Press Release -
